Acasti Pharma ACST

$ 3.37 4.01%

Quarterly report 2024-Q3
added 11-13-2024

Acasti Pharma Balance Sheet 2011-2024 | ACST

Annual Balance Sheet Acasti Pharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-27.4 M	-30 M	-	-	-15.5 M	-5.12 M	-	-2.23 M	-1.05 M	-607 K	-1.17 M	-1.6 M	-329 K
Long Term Debt	410 K	191 K	-	-	-	1.25 M	-	-	-	-	-	-	-
Long Term Debt Current	75 K	104 K	86 K	76 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	12.2 M	6.22 M	-	115 K	1.88 M	10 M	-	-	4.27 M
Total Current Liabilities	3.41 M	3.26 M	1.58 M	7.4 M	-	-	-	-	-	-	-	-	-
Total Liabilities	11.2 M	20.4 M	6.8 M	-	25.8 M	11.4 M	-	957 K	3.18 M	11.1 M	2.39 M	1.27 M	5.24 M
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-198 M	-156 M	-146 M	-	-92.8 M	-56 M	-	-29.2 M	-26.6 M	-28.5 M	-19.6 M	-13.2 M	-14.3 M
Total Assets	79.1 M	129 M	62.5 M	14 K	36.3 M	17.8 M	-	21 M	29.7 M	41 M	11.9 M	15.8 M	3.4 M
Cash and Cash Equivalents	27.9 M	30.3 M	50.9 M	14.2 M	-	-	-	-	-	-	-	-	-
Book Value	68 M	108 M	55.7 M	14 K	10.5 M	6.37 M	-	20.1 M	26.6 M	29.9 M	9.5 M	14.6 M	-1.84 M
Total Shareholders Equity	68 M	108 M	55.7 M	13 M	11 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Acasti Pharma

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	410 K	430 K	450 K	174 K	191 K	-	-	-	-	-	38 K	56 K	71 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	9.22 M	10.4 M	11.5 M	11.5 M	9.02 M	11.2 M	20.1 M	20.7 M	20.5 M	20.4 M	3.16 M	5.59 M	7 M	6.8 M	4.59 M	4.96 M	9.11 M	9.86 M	-	-	-	25.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-217 M	-214 M	-208 M	-206 M	-202 M	-198 M	-169 M	-165 M	-160 M	-156 M	-152 M	-148 M	-149 M	-146 M	-140 M	-137 M	-131 M	-126 M	-	-	-	-101 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	65.3 M	69.7 M	76.2 M	78.2 M	73 M	79.1 M	117 M	121 M	125 M	129 M	114 M	120 M	60.5 M	62.5 M	30.3 M	13.8 M	20.1 M	22.9 M	-	-	-	36.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	15.2 M	19.4 M	18.5 M	10.6 M	5.41 M	27.9 M	26.2 M	34.9 M	38.4 M	30.3 M	33 M	36.9 M	41 M	50.9 M	26.5 M	11.6 M	12.1 M	14.2 M	16.9 M	2.62 M	1.11 M	16.9 M	6.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	56.1 M	59.4 M	64.7 M	66.7 M	64 M	68 M	96.7 M	100 M	104 M	108 M	111 M	114 M	53.5 M	55.7 M	25.7 M	8.87 M	11 M	13 M	-	-	-	11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	56.1 M	59.4 M	64.7 M	66.7 M	64 M	68 M	96.7 M	100 M	104 M	108 M	111 M	114 M	53.5 M	55.7 M	25.7 M	25.7 M	8.87 M	11 M	-4.29 M	-759 K	3.28 M	11 M	-	-	-	7.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency